Regulatory and microbiological safety issues surrounding cell and tissue-engineering products

Area of Science:

• Biotherapeutics
• Regenerative Medicine
• Cellular Therapy

Background:

• Cell and tissue-engineered products represent a promising frontier in novel therapeutics.
• These advanced therapies, utilizing living cells, introduce unique safety considerations.
• A primary concern is the potential transmission of human viruses.

Purpose of the Study:

• To address the safety challenges associated with cell and tissue-engineered products.
• To explore alternative safety assurance strategies for products with short shelf lives.
• To highlight the importance of raw material testing in ensuring therapeutic safety.

Main Methods:

• Risk assessment of viral transmission pathways in cell-based products.
• Development of rigorous testing protocols for raw materials used in manufacturing.
• Evaluation of the limitations of traditional product characterization for short-shelf-life biologics.

Main Results:

• Viral transmission is a significant safety risk for cell and tissue-engineered products.
• Extensive raw material testing serves as a critical control point for ensuring product safety.
• Traditional extensive product testing is often infeasible due to the short shelf life of these novel therapies.

Conclusions:

• Ensuring the safety of cell and tissue-engineered products requires a shift towards robust raw material evaluation.
• Careful risk assessment and stringent raw material testing are essential to mitigate viral transmission risks.
• These strategies compensate for the inability to perform comprehensive product testing on short-shelf-life biotherapeutics.